Recap – LustgartenLIVE!: Sprint to Discovery

Four minutes on the clock. Six researchers ready to share their work. And a community eager to learn what’s next in pancreatic cancer research.
The second annual LustgartenLIVE!: Sprint to Discovery put the next generation of scientific talent in the spotlight for a fast-paced showcase of innovative research supported by the Lustgarten Foundation’s LABS (Lustgarten Advancing Breakthrough Science) Program.
With just four minutes to present, each researcher distilled down complex science into compelling presentations, including the questions they’re tackling, the discoveries they’re pursuing, and their potential to improve outcomes for pancreatic cancer patients.
Hosted by Lustgarten Foundation CEO Linda Tantawi and Vice President of Research Andrew Rakeman, PhD, the interactive event connected audiences directly with the scientists behind emerging discoveries, inviting viewers to engage with the research and vote for the presentation that stood out most.
SIX RESEARCHERS. SIX BOLD IDEAS.
From overcoming treatment resistance to developing new immunotherapies, each researcher offered a unique perspective on advancing pancreatic cancer research.

Vasiliki Pantazopoulou, PhD | Salk Institute
When the Drug Stops Working: Tackling Resistance to RAS Inhibitors in Pancreatic Cancer
Exploring how pancreatic tumors develop resistance to RAS inhibitors and identifying potential treatment combinations that could help extend their effectiveness.

Tushar Nichakawade, PhD | Johns Hopkins
Two-Factor Authentication for CAR T Cells Targeting Pancreatic Cancer
Engineering immune cells that recognize two specific markers before attacking cancer, with the goal of making CAR T-cell therapy safer and more effective.

Agata Lemiesz Patriotis, PhD | Massachusetts Institute of Technology (MIT)
Beyond KRAS: How Additional Mutations Shape Pancreatic Cancer and Point to New Treatments
Studying how mutations in the ARID1A gene influence tumor growth and treatment resistance, potentially uncovering new vulnerabilities for targeted therapies.

Jérémy Nigri, PhD | Cold Spring Harbor Laboratory
Disconnecting the Nerves that Drive Pancreatic Cancer
Investigating how nerves and surrounding cells help pancreatic tumors grow, revealing potential new opportunities to disrupt cancer progression.

Saraswathy Vaidyanathan, PhD | Dana-Farber Cancer Institute
Same Seed, Different Soil: How the Site of Metastasis Shapes Pancreatic Cancer Behavior
Examining how the environments of different organs influence pancreatic cancer after it spreads, with the goal of guiding more personalized treatment strategies.

Henry Wang, MD, PhD | Johns Hopkins
Training the Immune System to Fight Pancreatic Cancer with an Off-the-Shelf mRNA Vaccine
Developing an mRNA vaccine targeting mutated KRAS to help the immune system recognize pancreatic cancer, with potential applications in treatment and prevention.
INVESTING IN THE SCIENTISTS BEHIND TOMORROW’S BREAKTHROUGHS
Breakthroughs don’t happen in isolation. They require collaboration, access to resources, and opportunities for promising scientists to pursue ideas that could change the course of pancreatic cancer research. Through the LABS Program, Lustgarten provides sustained support to leading researchers and institutions, fostering an environment where emerging scientific talent can explore innovative approaches, share expertise, and accelerate discovery.
Following their presentations, panelists discussed how collaboration across institutions and scientific disciplines is accelerating progress. From sharing advanced technologies and laboratory models to connecting findings with clinical insights, these partnerships are strengthening a research ecosystem that builds on today’s momentum to bring promising discoveries closer to patients.
The conversation also highlighted the essential role patients play in research. By contributing tissue and blood samples, patients help scientists better understand how the disease develops, spreads, and responds to treatment, ensuring research is grounded in the realities of the disease.
While their approaches differed, each postdoctoral researcher demonstrated what is possible when emerging talent has the resources and support to pursue bold ideas. Their work is a reminder that the breakthroughs patients need tomorrow depend on the investments we make in research today.
Watch the full Sprint to Discovery webinar:
The LABS Program is made possible, in part, by the generous support of the Bern Schwartz Family Foundation, KAAB Memorial Foundation, Warren Alpert Foundation, and Wasily Family Foundation.
Their commitment helps foster the scientific talent and collaborative research needed to advance progress against pancreatic cancer.